Shilpa Medicare shares witnessed a notable gain on October 4, following an important regulatory milestone. The company's 100% subsidiary, Shilpa Pharma Lifesciences, received the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for Desmopressin, a key API (Active Pharmaceutical Ingredient) used in treating diabetes insipidus.
At 09:24 am, Shilpa Medicare's stock was trading at ₹ 812.75 on the BSE, up by ₹ 6.85 or 0.85%, reflecting investor confidence after this development. For those engaged in share market investment, this move by Shilpa Pharma Lifesciences signals the company's growing potential in the global pharmaceutical industry.
Shilpa's Medicare progress in peptide manufacturing
Desmopressin, a synthetic peptide developed through solid-phase synthesis, helps to manage conditions like central diabetes insipidus and bedwetting by reducing excessive thirst and frequent urination. Shilpa Medicare's achievement of obtaining the CEP for this molecule demonstrates its prowess in handling complex chemical syntheses and manufacturing processes. According to Keshav Bhutada, Executive Director of Shilpa Pharma Lifesciences, this certification paves the way for the company's broader peptide portfolio, aligning with global quality standards.
Implications for investors
The certification not only showcases Shilpa's technical competence but also builds investor confidence. Investors looking into share market investment should note that such certifications often lead to improved revenue streams, especially as the company continues expanding its peptide offerings. Furthermore, Shilpa's progress isn't limited to diabetes treatments. In August, the company reported success in Phase 3 trials for NorUDCA, a drug aimed at treating Nonalcoholic Fatty Liver Disease (NAFLD), further strengthening its growth trajectory.
Key takeaways
For android only